Skip to content
drillr.ai
Sign up

09606.HK

Duality Biotherapeutics, Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 104.20
−4.75%
Ask drillr

  • Oct 29, 2026, 10:00 UTC

    Duality Biotherapeutics, Inc.' directors and senior management voluntarily committed not to sell or otherwise dispose of shares they directly or indirectly beneficially own for six months.

    Source:

  • Oct 29, 2026, 01:55 UTC

    Duality Biotherapeutics, Inc. repurchased 158,000 shares at HK$104.6–109.9 per share, for approximately HK$17,016,300.

    Source:

  • Oct 29, 2026, 01:31 UTC

    Duality Biotherapeutics, Inc. Chairman and CEO Zhu Zhongyuan plans to use his own funds to buy additional shares of the company on the open market, for an amount of up to US$5 million.

    Source:

  • Oct 27, 2026, 08:12 UTC

    Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.

    Source:

  • Oct 27, 2026, 05:13 UTC

    Daiichi Sankyo shares fell sharply after Duality Biotherapeutics, Inc.'s ESMO event was viewed negatively by the market.

    Source:

  • Oct 27, 2026, 05:03 UTC

    Duality Biotherapeutics, Inc. reported clinical activity for elfe-D monotherapy in platinum-resistant ovarian cancer at the 6 mg/kg and 9 mg/kg dose levels.

    Source:

  • Oct 27, 2026, 05:03 UTC

    Duality Biotherapeutics, Inc. announced clinical study results for elfetabart drozuntecan (DB-1311/BNT324, elfe-D) and DB-1310, including elfe-D combined with pumitamig and development progress in platinum-resistant ovarian cancer.

    Source:

  • Oct 27, 2026, 04:14 UTC

    Duality Biotherapeutics, Inc. reported positive phase III SAFFRON results for osimertinib plus savolitinib in 338 patients with EGFR-mutated, MET-overexpressing or amplified non-small cell lung cancer, including median progression-free survival of 7.6 months versus 5.4 months with chemotherapy and median overall survival of 17.8 months versus 12.9 months.

    Source:

  • Oct 27, 2026, 04:12 UTC

    Hong Kong-listed shares showed varied moves at midday, including Xiaomi Corp. down 4.2%, Lenovo Group Ltd. up 5.8%, and Duality Biotherapeutics, Inc. down 29.4%.

    Source:

  • Jul 3, 2026, 11:40 UTC

    Duality Biotherapeutics Inc's IPO on the STAR Market has been updated to 'under inquiry' by the Shanghai Stock Exchange.

    Source: